

William Slattery, CFA Vice President Listing Qualifications

By Electronic Mail

January 22, 2014

Mr. Jeffrey Thomas Chief, IT Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Dear Mr. Thomas:

This is to certify that on January 17, 2014 The Nasdaq Stock Market (the "Exchange") received from Akers Biosciences, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Stock, no par value per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Lattery

The NASDAQ OMX Group • 805 King Farm Blvd. • Rockville, MD 20850 • USA • www.nasdaqomx.com



Received SEC

JAN 222014

Washington, DC 20549 CERT NAS File No. 001 - 36268